|
The adjuvant combination PVP-AF04 enhances the antibody response towards SARS-CoV antigens
The adjuvant combination PVP-AF04 enhances the antibody response towards SARS-CoV antigens
Background
As of 2024, SARS-CoV-2 has caused over 1 million deaths in the United States and more than 7 million worldwide. As the virus continues to mutate, it is important to advance immunization efforts to combat the virus’s effects, especially...
Published: 3/24/2026
|
Updated: 5/8/2024
|
Inventor(s): Ofer Levy, Yoshine Saito, Francesco Borriello, David Dowling, Timothy Yu
Keywords(s):
Category(s): Technology Classifications > Disease Area > Infectious Disease, Technology Classifications > Disease Area > Infectious Disease > COVID-19, Technology Classifications > Invention Type > Vaccines > Adjuvants
|
|
Toll-like receptor 2 agonists as vaccine adjuvants
Toll-like receptor 2 agonists as vaccine adjuvants
Background
Vaccinations play an essential role in preventing infections in the population, reducing the number of deaths in vulnerable individuals, as well as preventing endemics of highly infectious diseases. Because of the protective nature of vaccinations, particularly for those in certain vulnerable...
Published: 3/24/2026
|
Updated: 5/31/2023
|
Inventor(s): Ofer Levy, David Dowling, Francesco Borriello, Spencer Brightman
Keywords(s): Adjuvants, Infectious Disease, Vaccine
Category(s): Technology Classifications > Invention Type, Technology Classifications > Invention Type > Vaccines, Technology Classifications > Disease Area, Technology Classifications > Disease Area > Infectious Disease, Technology Classifications > Disease Area > Oncology
|
|
A family of small molecule thiazole amides with in vitro adherence-, NFkB- and IRF-inducing activity towards human leukocytes and vaccine adjuvant in mice in vivo.
A Family of Small Molecule Thiazole Amides with in vitro Adherence Inducing Activity Towards Human Leukocytes and Vaccine Adjuvant in Mice in vivo
The small molecule family has multiple activities towards human leukocytes in vitro and adjuvant activity in vivo
Background
Since the immune system plays an essential role in major diseases such...
Published: 3/18/2026
|
Updated: 3/7/2023
|
Inventor(s): Ofer Levy, David Dowling, Francesco Borriello
Keywords(s):
Category(s): Technology Classifications > Invention Type, Technology Classifications > Invention Type > Vaccines, Technology Classifications > Disease Area, Technology Classifications > Disease Area > Infectious Disease, Technology Classifications > Disease Area > Oncology
|
|
STING Agonists as Immunomodulators and Vaccine Adjuvants
STING Agonists as Immunomodulators and Vaccine Adjuvants
STING agonists proven to be effective vaccine adjuvants and immunomodulators in newborns
Background
Infectious diseases are the leading cause of morbidity and mortality in early life and immunization is a key preventive strategy. Vaccine adjuvants can enhance, prolong, and modulate immune responses...
Published: 3/30/2026
|
Updated: 3/6/2023
|
Inventor(s): Ofer Levy, Carlo Pietrasanta, David Dowling, Francesco Borriello
Keywords(s): Immunology, Therapeutic, ZZCommon, ZZTherapeutics:Vaccines
Category(s): Technology Classifications > Invention Type, Technology Classifications > Invention Type > Vaccines, Technology Classifications > Disease Area, Technology Classifications > Disease Area > Infectious Disease
|